Search
Tiludronic acid
go.drugbank.com/drugs/DB01133ApprovedVet approvedWithdrawnTiludronate, or (4-chlorophenyl)thio-methylene-1,1-bisphosphonate, is a first generation bisphosphonate similar to [etidronic acid] and [clodronic acid]. … [A1923,A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification.
Categories: Drugs for Treatment of Bone DiseasesLebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigational[A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12 … Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.[L51374] It binds to a different epitope compared [tralokinumab].
Categories: Agents for Dermatitis, Excluding CorticosteroidsCarbopol 974P
go.drugbank.com/drugs/DB05384ApprovedWithdrawnThe compound, known as BufferGel, was in advanced clinical trials for its ability to prevent pregnancy, but was discontinued. … It was under development by ReProtect LLC. It is a gel that may help both block the spread of sexually transmitted diseases and reduce unwanted pregnancies.
Categories: Compounds used in a research, industrial, or household settingSusoctocog alfa
go.drugbank.com/drugs/DB11606ApprovedInvestigationalIt is the first recombinant porcine FVIII treatment approved for AHA that allows physicians to manage the treatment's efficacy and safety by measuring factor VIII activity levels in addition to clinical … Susoctocog alfa serves to temporarily restore the inhibited endogenous Factor VIII for effective hemostasis.
Nateglinide
go.drugbank.com/drugs/DB00731ApprovedOne minor metabolite, the isoprene, has the same potency as its parent compound. … The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents.
Teplizumab
go.drugbank.com/drugs/DB06606ApprovedInvestigational[L44096] In April 2026, the FDA approved an expanded indication for teplizumab, lowering the eligible age range from 8 years and older down to 1 year and older for patients with Stage 2 T1D.[L56140] … [A241490] Anti-CD3 therapy has traditionally been used to prevent graft-versus-host-disease in organ transplantation but more recently has been explored to prolong the onset of (T1D) in high-risk patients
Sermorelin
go.drugbank.com/drugs/DB00010ApprovedWithdrawnSermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing … hormone (GHRH or GRF) consisting of 44 amino acid residues
Categories: Tests for Pituitary FunctionElexacaftor
go.drugbank.com/drugs/DB15444ApprovedInvestigational[A187361] Elexacaftor, along with [VX-659], was designed to fill the need for an efficacious CF therapy for patients who are heterozygous for _F508del-CFTR_ and a gene that does not produce protein or … produces proteins unresponsive to ivacaftor or tezacaftor.
Hydroxyprogesterone caproate
go.drugbank.com/drugs/DB06789ApprovedHydroxyprogesterone caproate is a synthetic steroid hormone that is similar to medroxyprogesterone acetate and megestrol acetate. … In April 2023, the FDA withdrew its approval of Makena and its generics given an unfavorable risk-to-benefit assessment.[L46113]
Categories: Hormonal Contraceptives for Systemic UseDextropropoxyphene
go.drugbank.com/drugs/DB00647ApprovedIllicitWithdrawnThe drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. … Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome